Qiagen N.V. Stock price

Equities

QGEN

NL0015001WM6

Biotechnology & Medical Research

Market Closed - Nyse 04:00:02 2024-03-28 pm EDT 5-day change 1st Jan Change
42.99 USD +0.56% Intraday chart for Qiagen N.V. -1.58% -3.98%
Sales 2024 * 2.01B Sales 2025 * 2.16B Capitalization 9.52B
Net income 2024 * 397M Net income 2025 * 446M EV / Sales 2024 * 4.88 x
Net Debt 2024 * 303M Net cash position 2025 * 281M EV / Sales 2025 * 4.29 x
P/E ratio 2024 *
24.2 x
P/E ratio 2025 *
21.3 x
Employees 5,361
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.45%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.56%
1 week-1.58%
Current month+0.47%
1 month-0.49%
3 months-4.29%
6 months+5.07%
Current year-3.98%
More quotes
1 week
42.08
Extreme 42.08
43.60
1 month
42.08
Extreme 42.08
45.07
Current year
42.08
Extreme 42.08
47.29
1 year
35.81
Extreme 35.8144
49.18
3 years
35.81
Extreme 35.8144
59.79
5 years
25.81
Extreme 25.8144
60.82
10 years
20.83
Extreme 20.8335
60.82
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 15-01-31
Founder 69 96-04-28
Director of Finance/CFO 56 98-12-31
Members of the board TitleAgeSince
Director/Board Member 75 11-05-31
Founder 69 96-04-28
Chairman 66 13-06-25
More insiders
Date Price Change Volume
24-03-28 42.99 +0.56% 1,065,393
24-03-27 42.75 +0.12% 1,012,975
24-03-26 42.7 -0.28% 922,372
24-03-25 42.82 -2.35% 913,880
24-03-22 43.85 +0.39% 799,504

Delayed Quote Nyse, March 28, 2024 at 04:00 pm EDT

More quotes
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
42.99 USD
Average target price
51 USD
Spread / Average Target
+18.64%
Consensus
  1. Stock
  2. Equities
  3. Stock Qiagen N.V. - Nyse